EUVIMED · CrossrefJournal
International Journal of Urology
ISSN 0919-8172 · Wiley
Latest articles
Prolonged and Nocturnal Hypoglycemia Following Resection of Pheochromocytoma and Paraganglioma: A Prospective Study Using Intermittent‐Scanning Continuous Glucose Monitoring
A Trial‐Level Benefit–Toxicity Mapping Framework for Adjuvant Therapy in Renal Cell Carcinoma: A Focused Review
External Validation of Existing Nomograms on Indian Prostate Biopsy Data
Editorial Comment to Development and Validation of the JIKEI ‐ YAYOI Score for Predicting Castration Resistance in Metastatic Castration‐Sensitive Prostate Cancer Treated With ARSI ‐Based Doublet Therapy
Magnetic Resonance Imaging Findings and Prostate‐Specific Antigen Density‐Based Risk Stratification for Deferring a Separate Preoperative Biopsy in Candidates for Holmium Laser Enucleation of the Prostate
Five‐Year Clinical Outcomes Following Nephrectomy for Renal Cell Carcinoma: Evidence From a Nationwide Japanese Surgical Registry
Sensitivity of mHSPC Overall Survival Network Estimates to the Historical Docetaxel Bridge
Beyond Association: Clarifying the Biological and Clinical Value of Urinary EphA2 in Bladder Cancer
Beyond Surgical Technique: Prostate Cancer Assessment and Treatment Sequencing Before HoLEP
Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis
Urethroplasty for Anterior Urethral Stricture in Men With Non‐Muscle‐Invasive Bladder Cancer: Feasibility and Durability of a Pragmatic Recurrence‐Free Interval‐Oriented Strategy
Clinical Outcomes of Percutaneous Cryoablation for Localized Renal Cell Carcinoma in Very Elderly Patients
Phospho‐ LATS1 /2 Immunoreactivity and Survival in Muscle‐Invasive Bladder Cancer: A Quantitative Immunohistochemical Study
Oligoprogression and Metastasis‐Directed Therapy During Systemic Therapy for Metastatic Renal Cell Carcinoma
Editorial Comment to Intravesical and Intraurethral Indocyanine Green for Structural Guidance During Robot‐Assisted Radical Prostatectomy: An Exploratory Trial
Editorial Comment on Prevalence and Associated Factors of Erectile Dysfunction in Japanese Adolescent and Young Adult ( AYA ) Male Cancer Survivors
Editorial Comment on Pre‐Procedural Gamma‐Glutamyltransferase‐to‐Lymphocyte Ratio as an Adjunctive Biomarker for Differentiating Hunner‐Type Interstitial Cystitis From Bladder Pain Syndrome
Clinical Significance of MRI ‐Suspicious Lesion Visibility on 29‐ MHz Micro‐Ultrasound During MRI –Ultrasound Fusion Targeted Prostate Biopsy
Impact of Adjuvant Immune Checkpoint Inhibitors and Chemotherapy on Survival Outcomes in High‐Risk Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Study
Pelvic Floor Muscle Reactivity Measured Using M‐Mode Ultrasonography in Males With Post‐Prostatectomy Incontinence
Beyond Layer Recognition: Why AI Navigation in Robot‐Assisted Radical Prostatectomy Needs Functional‐Outcome‐Driven Validation
Clinical Practice in Japan for Treating Adrenocortical Carcinoma, Collecting Duct Carcinoma of the Kidney, and Small Cell Carcinoma of the Bladder: A Nationwide Survey
Impact of Prior Holmium Laser Enucleation of the Prostate on Outcomes After Robot‐Assisted Radical Prostatectomy
Urinary Extracellular Vesicle–Associated EphA2 Predicts Intravesical Recurrence in Bladder Cancer
Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis
Development and Validation of the JIKEI ‐ YAYOI Score for Predicting Castration Resistance in Metastatic Castration‐Sensitive Prostate Cancer Treated With ARSI ‐Based Doublet Therapy
Survival Benefit of ARSI Therapy in Japanese mCSPC : A Systematic Review and Meta‐Analysis
Consensus‐Based Development of a Surgical Checklist for Transurethral Resection of Bladder Tumor: An Initiative of the Japanese Society of Urologic Oncology
Prognostic Value of Inflammatory Biomarkers as Continuous Variables in Metastatic Renal Cell Carcinoma: Linearity Assessment, Proportional Hazards Assumption Testing, and Time‐Varying Effects
Editorial Comment to Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study
Volumes
2026 · 3172025 · 3562024 · 2842023 · 2502022 · 3482021 · 3112020 · 2742019 · 3132018 · 2572017 · 2232016 · 2772015 · 3232014 · 4162013 · 2852012 · 2542011 · 2212010 · 2332009 · 2232008 · 2512007 · 2912006 · 3872005 · 2402004 · 2532003 · 1762002 · 1632001 · 1822000 · 1201999 · 1261998 · 1461997 · 1411996 · 1731995 · 971994 · 66
EUVIMED